X
[{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$156.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,085.0 million","upfrontCash":"$85.0 million","newsHeadline":"Astra Zeneca Announces Agreement with Quell Therapeutics to Develop, Manufacture and Commercialise Engineered T-Regulatory Cell Therapies for Autoimmune Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"N\/A","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"N\/A"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quell's QEL-001 CAR-Treg Therapy Moves to Phase 1\/2 Trial for Liver Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Quell Therapeutics
Filters
Companies By Therapeutic Area
Details:
QEL-001, its autologous engineered CAR-Treg cell therapy, which is being investigated in Phase 1/2 trial in patients with liver transplant patients.
Lead Product(s):
QEL-001
Therapeutic Area: Immunology
Product Name: QEL-001
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 04, 2024
Details:
The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell therapy candidates.
Lead Product(s):
Treg-based Cell Therapy
Therapeutic Area: Endocrinology
Product Name: Undisclosed
Highest Development Status: N/A
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
AstraZeneca
Deal Size: $2,085.0 million
Upfront Cash: $85.0 million
Deal Type: Collaboration
June 09, 2023
Details:
Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platform.
Lead Product(s):
QEL-001
Therapeutic Area: Immunology
Product Name: QEL-001
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Jeito Capital
Deal Size: $156.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
November 29, 2021
Details:
The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).
Lead Product(s):
Multi-modular Engineered Treg Cell Therapy
Therapeutic Area: Immunology
Product Name: QEL-001
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 27, 2021